Toward Improvement of Screening Through Mass Spectrometry-based Proteomics: Ovarian Cancer As a Case Study

Overview

Journal Int J Mass Spectrom

Publisher Elsevier

Date 2021 Nov 8

PMID 34744497

Citations 4

Authors

Gordon T Luu

Laura M Sanchez

Affiliations

Soon will be listed here.

Abstract

Ovarian cancer is one of the leading causes of cancer related deaths affecting United States women. Early-stage detection of ovarian cancer has been linked to increased survival, however, current screening methods, such as biomarker testing, have proven to be ineffective in doing so. Therefore, further developments are necessary to be able to achieve positive patient prognosis. Ongoing efforts are being made in biomarker discovery towards clinical applications in screening for early-stage ovarian cancer. In this perspective, we discuss and provide examples for several workflows employing mass spectrometry-based proteomics towards protein biomarker discovery and characterization in the context of ovarian cancer; workflows include protein identification and characterization as well as intact protein profiling. We also discuss the opportunities to merge these workflows for a multiplexed approach for biomarkers. Lastly, we provide our insight as to future developments that may serve to enhance biomarker discovery workflows while also considering translational potential.

Citing Articles

Branched-chain amino acid catabolism promotes ovarian cancer cell proliferation via phosphorylation of mTOR.

Lusk H, Haughan M, Bergsten T, Burdette J, Sanchez L bioRxiv. 2024; .

PMID: 39464074 PMC: 11507863. DOI: 10.1101/2024.10.15.618560.

An Integrated Approach to Protein Discovery and Detection From Complex Biofluids.

Luu G, Ge C, Tang Y, Li K, Cologna S, Godwin A Mol Cell Proteomics. 2023; 22(7):100590.

PMID: 37301378 PMC: 10388710. DOI: 10.1016/j.mcpro.2023.100590.

Mass Spectrometry-Based Proteomics of Epithelial Ovarian Cancers: A Clinical Perspective.

Qian L, Sun R, Xue Z, Guo T Mol Cell Proteomics. 2023; 22(7):100578.

PMID: 37209814 PMC: 10388592. DOI: 10.1016/j.mcpro.2023.100578.

Application of Proteomics in Pancreatic Ductal Adenocarcinoma Biomarker Investigations: A Review.

Vellan C, Jayapalan J, Yoong B, Abdul-Aziz A, Mat-Junit S, Subramanian P Int J Mol Sci. 2022; 23(4).

PMID: 35216204 PMC: 8879036. DOI: 10.3390/ijms23042093.

References

Ntai I, Fornelli L, DeHart C, Hutton J, Doubleday P, LeDuc R . Precise characterization of KRAS4b proteoforms in human colorectal cells and tumors reveals mutation/modification cross-talk. Proc Natl Acad Sci U S A. 2018; 115(16):4140-4145. PMC: 5910823. DOI: 10.1073/pnas.1716122115. View

Dochez V, Caillon H, Vaucel E, Dimet J, Winer N, Ducarme G . Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. J Ovarian Res. 2019; 12(1):28. PMC: 6436208. DOI: 10.1186/s13048-019-0503-7. View

Meys E, Kaijser J, Kruitwagen R, Slangen B, Van Calster B, Aertgeerts B . Subjective assessment versus ultrasound models to diagnose ovarian cancer: A systematic review and meta-analysis. Eur J Cancer. 2016; 58:17-29. DOI: 10.1016/j.ejca.2016.01.007. View

Milani P, Murray D, Barnidge D, Kohlhagen M, Mills J, Merlini G . The utility of MASS-FIX to detect and monitor monoclonal proteins in the clinic. Am J Hematol. 2017; 92(8):772-779. DOI: 10.1002/ajh.24772. View

Albrethsen J, Kaas A, Schonle E, Swift P, Kocova M, Gammeltoft S . Evaluation of a type 1 diabetes serum cohort by SELDI-TOF MS protein profiling. Proteomics Clin Appl. 2012; 3(3):383-93. DOI: 10.1002/prca.200800063. View

Zhang W, Ou X, Wu X . Proteomics profiling of plasma exosomes in epithelial ovarian cancer: A potential role in the coagulation cascade, diagnosis and prognosis. Int J Oncol. 2019; 54(5):1719-1733. PMC: 6438431. DOI: 10.3892/ijo.2019.4742. View

Kawakami E, Tabata J, Yanaihara N, Ishikawa T, Koseki K, Iida Y . Application of Artificial Intelligence for Preoperative Diagnostic and Prognostic Prediction in Epithelial Ovarian Cancer Based on Blood Biomarkers. Clin Cancer Res. 2019; 25(10):3006-3015. DOI: 10.1158/1078-0432.CCR-18-3378. View

Goff B, Agnew K, Neradilek M, Gray H, Liao J, Urban R . Combining a symptom index, CA125 and HE4 (triple screen) to detect ovarian cancer in women with a pelvic mass. Gynecol Oncol. 2017; 147(2):291-295. DOI: 10.1016/j.ygyno.2017.08.020. View

Sandri M, Bottari F, Franchi D, Boveri S, Candiani M, Ronzoni S . Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome. Gynecol Oncol. 2012; 128(2):233-8. DOI: 10.1016/j.ygyno.2012.11.026. View

10.

Marshall J, Jankowski A, Furesz S, Kireeva I, Barker L, Dombrovsky M . Human serum proteins preseparated by electrophoresis or chromatography followed by tandem mass spectrometry. J Proteome Res. 2004; 3(3):364-82. DOI: 10.1021/pr034039p. View

11.

Staudt A, Wenkel S . Regulation of protein function by 'microProteins'. EMBO Rep. 2010; 12(1):35-42. PMC: 3024132. DOI: 10.1038/embor.2010.196. View

12.

Donnelly D, Rawlins C, DeHart C, Fornelli L, Schachner L, Lin Z . Best practices and benchmarks for intact protein analysis for top-down mass spectrometry. Nat Methods. 2019; 16(7):587-594. PMC: 6719561. DOI: 10.1038/s41592-019-0457-0. View

13.

Murray D, Puig N, Kristinsson S, Usmani S, Dispenzieri A, Bianchi G . Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report. Blood Cancer J. 2021; 11(2):24. PMC: 7873248. DOI: 10.1038/s41408-021-00408-4. View

14.

Jannetto P, Fitzgerald R . Effective Use of Mass Spectrometry in the Clinical Laboratory. Clin Chem. 2015; 62(1):92-8. DOI: 10.1373/clinchem.2015.248146. View

15.

Munteanu B, Hopf C . Emergence of whole-cell MALDI-MS biotyping for high-throughput bioanalysis of mammalian cells?. Bioanalysis. 2013; 5(8):885-93. DOI: 10.4155/bio.13.47. View

16.

Miller R, Smith A, DeSimone C, Seamon L, Goodrich S, Podzielinski I . Performance of the American College of Obstetricians and Gynecologists' ovarian tumor referral guidelines with a multivariate index assay. Obstet Gynecol. 2011; 117(6):1298-1306. DOI: 10.1097/AOG.0b013e31821b1d80. View

17.

Engvall E, Perlmann P . Enzyme-linked immunosorbent assay, Elisa. 3. Quantitation of specific antibodies by enzyme-labeled anti-immunoglobulin in antigen-coated tubes. J Immunol. 1972; 109(1):129-35. View

18.

Macklin A, Khan S, Kislinger T . Recent advances in mass spectrometry based clinical proteomics: applications to cancer research. Clin Proteomics. 2020; 17:17. PMC: 7247207. DOI: 10.1186/s12014-020-09283-w. View

19.

Albrethsen J . The first decade of MALDI protein profiling: a lesson in translational biomarker research. J Proteomics. 2011; 74(6):765-73. DOI: 10.1016/j.jprot.2011.02.027. View

20.

Rogers M, Clarke P, Noble J, Munro N, Paul A, Selby P . Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility. Cancer Res. 2003; 63(20):6971-83. View